Skip to content
In English |
En español
Search
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 12
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
4/7/2005
1.
Phase II Study of Monoclonal Antibody 3F8 with Sargramostim (GM-CSF) in Patients with Advanced Neuroblastoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
2 to 21
Other
MSKCC-94018
NCI-V94-0416, NCT00002560
Last Modified:
12/6/2007
2.
Phase II Study of Intensive Multimodality Therapy for Poor Risk Neuroblastoma: Sequential Cyclophosphamide, Doxorubicin, and Vincristine Along With Cisplatin and Etoposide, External-Beam Radiotherapy, and Radioimmunotherapy With Iodoine I 131 Monoclonal Antibody (MOAB 3F8) Followed by Autologous Bone Marrow Transplantation and Immunotherapy With MOAB 3F8
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
over 1 at diagnosis
Other
MSKCC-94011A1
MSKCC-FDR001041, NCI-V95-0622, NCT00002634
Last Modified:
10/3/2003
 
First Published:
11/1/1999
3.
Phase II Study of Monoclonal Antibody 3F8, Etoposide, and Isotretinoin in Patients With High-Risk Neuroblastoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
Not specified
NCI
MSKCC-IRB-99033
NCI-G99-1599, NCT00004110
Last Modified:
4/7/2005
 
First Published:
7/1/2002
4.
Phase II Study of Multimodality Therapy Comprising Dose-Intensive Induction Chemotherapy, Monoclonal Antibody 3F8, Surgery, Myeloablative Chemotherapy, Autologous or Syngeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation, Radiotherapy, and Isotretinoin in Patients With Advanced Neuroblastoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
50 and under
NCI
MSKCC-00065
NCI-G02-2083, NCT00040872
Last Modified:
8/1/1991
5.
Phase II Study of Antiganglioside GD2-Specific Mouse MOAB 3F8 in Patients with Neuroblastoma in Early Relapse (Summary Last Modified 08/91)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
under 18
MSKCC-87059
NCI-V88-0353
Last Modified:
4/1/2000
6.
Phase II Study of Adjuvant Therapy with Antiganglioside GD2-Specific Mouse Monoclonal Antibody 3F8 for Metastatic Neuroblastoma in Second Remission
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
under 18
Other
MSKCC-87118
NCI-V88-0357, NCT00002458
Last Modified:
1/1/1991
7.
Phase II Study of the N6 Regimen Involving Intensive Chemotherapy with CAV (CTX/DOX/VCR) and PVP (VP-16/CDDP) with Adjuvant MOAB 3F8, plus Surgery and Radiotherapy as Appropriate, in Patients with Poor-Risk Neuroblastoma (Summary Last Modified 01/91)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
any age
MSKCC-89175A2
NCI-V90-0023
Last Modified:
7/19/2007
 
First Published:
7/23/2004
8.
Phase II Study of Monoclonal Antibody 3F8, Beta-Glucan, Isotretinoin and Sargramostim (GM-CSF) in Patients With High-Risk Refractory Neuroblastoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
Any age
NCI
MSKCC-04050
NCT00089258
Last Modified:
11/5/2004
 
First Published:
5/1/2002
9.
Phase I Study of beta-Glucan and Monoclonal Antibody 3F8 in Patients With Metastatic Neuroblastoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
Under 50
NCI
MSKCC-01075
NCI-G02-2067, NCT00037011
Last Modified:
8/1/1988
10.
Phase I Study of Anti-GD2 (3F8) and Anti-GD3 (R24) Mouse Monoclonal Antibodies in Patients with Metastatic Melanoma or Soft Tissue Sarcoma (Summary Last Modified 08/88)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
18 and over
MSKCC-86066
NCI-V88-0387
Select All on One Page
1
2
Next >
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute